Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to Insider Trades Newsletter so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email
NYSEAMERICAN:NBY

NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis

→ This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad)
Free NBY Stock Alerts
$0.19
+0.07 (+58.94%)
(As of 02:15 PM ET)
Compare
Today's Range
$0.13
▼
$0.23
50-Day Range
N/A
52-Week Range
$0.07
▼
$1.28
Volume
128.45 million shs
Average Volume
6.23 million shs
Market Capitalization
$793,585.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest
NBY stock logo

About NovaBay Pharmaceuticals Stock (NYSEAMERICAN:NBY)

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

NBY Stock Price History

NBY Stock News Headlines

May 13, 2024 | finance.yahoo.com
NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q1 2024 Earnings Call Transcript
May 12, 2024 | americanbankingnews.com
NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Short Interest Down 34.2% in April
May 8, 2024 | markets.businessinsider.com
NovaBay Pharmaceuticals is about to announce earnings — here's what Wall Street expects
April 17, 2024 | finance.yahoo.com
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
April 17, 2024 | markets.businessinsider.com
Buy Rating Maintained for NovaBay Pharma Amid Strategic Refocus and Resilient Revenue Performance
March 27, 2024 | finance.yahoo.com
NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q4 2023 Earnings Call Transcript
March 27, 2024 | finance.yahoo.com
Q4 2023 NovaBay Pharmaceuticals Inc Earnings Call
March 15, 2024 | barrons.com
NovaBay Pharmaceuticals Inc.
March 14, 2024 | markets.businessinsider.com
NovaBay Pharmaceuticals To Sell DERMAdoctor Skincare Business - Quick Facts
March 13, 2024 | markets.businessinsider.com
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
February 26, 2024 | finance.yahoo.com
NovaBay Pharmaceuticals, Inc. (NBY)
January 30, 2024 | finance.yahoo.com
NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales
January 29, 2024 | msn.com
Why ZIM Integrated Shipping Services Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
January 9, 2024 | finance.yahoo.com
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network
December 6, 2023 | finance.yahoo.com
NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic Membranes
November 12, 2023 | finance.yahoo.com
NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q3 2023 Earnings Call Transcript
November 9, 2023 | benzinga.com
Recap: NovaBay Pharmaceuticals Q3 Earnings
November 9, 2023 | finance.yahoo.com
NovaBay Pharmaceuticals Reports Third Quarter 2023 Financial Results
November 2, 2023 | finance.yahoo.com
NovaBay Pharmaceuticals to Hold Third Quarter 2023 Conference Call on November 9, 2023
October 21, 2023 | thestreet.com
NovaBay Pharmaceuticals: CEO Interview
October 11, 2023 | finance.yahoo.com
NovaBay Pharmaceuticals Expands Physician Dispensed Sales Channel with New Avenova Programs
October 2, 2023 | finance.yahoo.com
NovaBay Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference
September 11, 2023 | marketwatch.com
NovaBay Pharma Shares Rise 42% After Deal With BioStem Technologies
September 11, 2023 | markets.businessinsider.com
NovaBay Pharma Agrees With BioStem To Commercialize Amniotic Tissue Allograft As Avenova Allograft
September 11, 2023 | benzinga.com
Why NovaBay Pharmaceuticals Stock Is Blasting Higher
See More Headlines

Company Calendar

Last Earnings
3/26/2024
Today
5/20/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:NBY
CUSIP
N/A
CIK
1389545
Web
novabay.com
Phone
(510) 899-8800
Fax
510-474-1577
Employees
24
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($9.9465)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-10,610,000.00
Net Margins
-79.70%
Pretax Margin
-79.70%
Return on Equity
-146.20%
Return on Assets
-69.63%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.85
Quick Ratio
1.25

Sales & Book Value

Annual Sales
$14.40 million
Price / Sales
0.05
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.53 per share
Price / Book
0.11

Miscellaneous

Outstanding Shares
4,210,000
Free Float
4,160,000
Market Cap
$695,071.00
Optionable
Not Optionable
Beta
2.82

Key Executives

  • Mr. Justin M. Hall Esq. (Age 46)
    President, CEO, General Counsel, Chief Compliance Officer, Corporate Secretary & Director
    Comp: $364.15k
  • Mr. Tommy Law (Age 39)
    Controller, Interim CFO & Treasurer
    Comp: $155.48k

Key Competitors

View All Competitors

NBY Stock Analysis - Frequently Asked Questions

How have NBY shares performed in 2024?

NovaBay Pharmaceuticals' stock was trading at $0.1802 on January 1st, 2024. Since then, NBY stock has increased by 7.9% and is now trading at $0.1945.
View the best growth stocks for 2024 here.

Are investors shorting NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 137,000 shares, a drop of 34.2% from the April 15th total of 208,100 shares. Based on an average trading volume of 2,410,000 shares, the short-interest ratio is currently 0.1 days. Currently, 0.4% of the company's stock are short sold.
View NovaBay Pharmaceuticals' Short Interest.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) issued its quarterly earnings results on Tuesday, March, 26th. The biopharmaceutical company reported ($0.95) EPS for the quarter. The biopharmaceutical company earned $3.73 million during the quarter. NovaBay Pharmaceuticals had a negative trailing twelve-month return on equity of 146.20% and a negative net margin of 79.70%.

When did NovaBay Pharmaceuticals' stock split?

Shares of NovaBay Pharmaceuticals reverse split before market open on Wednesday, November 16th 2022. The 1-35 reverse split was announced on Wednesday, November 16th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of NovaBay Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Bionano Genomics (BNGO), Heat Biologics (HTBX), iBio (IBIO), Matinas BioPharma (MTNB), Novan (NOVN), ADMA Biologics (ADMA) and Vaxart (VXRT).

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:NBY) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Dems have chosen Biden replacement?
Paradigm Press
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1!
Huge Alerts
This Could be Your “Big Money” AI Moment
InvestorPlace
Digitizing the $11T commodities sector with one tiny stock
Resource Stock Digest
This military-backed stock “owns” AI market
Porter & Company
New Options need New Trading Strategies
Netpicks